Rate this article:
This image is taken from Dhawiwal et al (BJUI 2019). It schematically shows mechanism of action for immunotherapy for urothelial carcinoma.
Programmed death ligand 1 (PD-L1) is found on the tumour cell. Various Immune checkpoint inhibitors act on these (anti-PD-L1) e.g. atezolizumab, durvalumab, avelumab.
Cytotoxic T-lymphocyte associated protein4 (CTLA-4) are expressed on T-cells. Examples of anti-CTLA-4 agents are ipilimumab and tremelimumab.
Picture Quiz Archive
I agree to the Terms & Conditions
Notify me of follow-up comments by email.
Notify me of new posts by email.
Please note that all submitted comments will be reviewed by the BJUI Web Team before they are considered for publishing on the site. Comments may take up to 48 hours to go live. If you have made a comment which has not appeared live after this time and you wish to discuss this matter further, please contact us.